Targeted suppression of FTO with small-molecule inhibitors CS1 and CS2 can inhibit tumor proliferation through several pathways, including blockage of immune checkpoints (LILRB4) to suppress CSCs, induction of tumor cell cycle arrest (G0 phase), and suppression of immune escape through increasing tumor sensitivity to T cells, confirming the holistic nature of TME [190]. The gene discussed is LILRB4; the disease is neoplasm.